Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received a grant of 4,540 shares of common stock for the pay period ending May 15, 2026, as salary paid in stock instead of cash. The shares were issued fully vested under the company’s 2019 equity incentive plan at a reference price of $3.58, the closing price on May 15, 2026.
Following this grant, Dr. Armen directly holds 351,323 common shares, with additional indirect holdings in IRA accounts and entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
Agenus Inc. reported that its Senior Director, Financial Reporting and Compliance and Principal Accounting Officer, Austin Charette, has decided to resign. He informed the company on May 12, 2026, and his resignation will be effective May 29, 2026. The filing does not describe any replacement or changes to broader strategy, focusing solely on this leadership transition in the finance function.
Agenus Inc. reported a sharp swing to profitability for the quarter ended March 31, 2026, driven by a major manufacturing asset sale and higher royalty revenue, while still facing significant financial risk.
Total revenue rose to $33.7 million, including $29.1 million of non-cash royalty revenue from GlaxoSmithKline vaccines using its QS‑21 adjuvant and $4.6 million of pre-commercial sales of botensilimab/balstilimab through early access programs. A $40.4 million gain on the sale of its Emeryville and Berkeley manufacturing facilities to Zydus contributed to net income of $39.2 million, or $1.03 per basic share.
The Zydus collaboration brought $91.0 million in cash at closing and up to $50.0 million of additional non-cash consideration tied to future manufacturing services, while Agenus retained significant royalty and milestone obligations, including a $263.4 million liability related to prior royalty financings. Cash and cash equivalents increased to $35.0 million from $3.0 million at year-end 2025, and subsequent at-the-market share sales added $11.7 million. Despite this liquidity improvement, the company disclosed substantial doubt about its ability to continue as a going concern without additional capital, citing a $2.1 billion accumulated deficit and the need to fund late-stage development and potential commercialization of botensilimab plus balstilimab.
Agenus Inc. reported much stronger results for the quarter ended March 31, 2026, helped by its strategic collaboration with Zydus and growing early access use of its BOT+BAL immunotherapy combination. Total revenue rose to $33.7 million, up from $24.1 million a year earlier, and net income improved to a profit of $39.2 million versus a $26.4 million loss in the prior-year quarter.
Cash and cash equivalents were $35.0 million as of March 31, 2026, compared with $18.5 million a year earlier, with an additional $11.7 million raised after quarter-end through an at-the-market equity program. The Zydus collaboration, which closed in January 2026, delivered $91 million of upfront capital including $75 million in cash for U.S. manufacturing facilities and a $16 million equity investment, plus up to $50 million in contingent payments tied to BOT+BAL production orders.
Agenus highlighted that approximately 1,300 patients have been treated with botensilimab and/or balstilimab and that its global Phase 3 BATTMAN trial in refractory MSS colorectal cancer began enrolling patients in April 2026. The company is focusing operating priorities on BOT+BAL while targeting about $50 million in annualized operating expenses to support development. It also noted that the SEC concluded its investigation in May 2026 with no enforcement action recommended and that a related putative securities class action was dismissed in its entirety by a U.S. District Court in March 2026.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 4,233 shares of Common Stock as salary paid in stock for the pay period ending May 1, 2026. The shares were valued at $3.84, the closing price of Agenus stock on May 1, 2026, and are fully vested on issuance.
Following this grant, Dr. Armen directly holds 346,783 Agenus shares. He also has indirect holdings through IRA accounts, the Garo Armen 2020 2 Year AG GRAT with 23,950 shares, and Pixie Partners with 5,000 shares, where he has a pecuniary interest in only part of the Pixie position.
Agenus Inc. is asking stockholders to approve several equity and governance proposals at its June 16, 2026 virtual annual meeting. The company highlights BOT+BAL immunotherapy data showing about 39% two-year overall survival across 400+ heavily pretreated patients and 42% two-year survival with 21‑month median overall survival in refractory MSS metastatic colorectal cancer without active liver metastases.
Agenus reports its first reimbursed revenues from a French compassionate access program and additional paid named‑patient use in multiple countries. Management cites a strategic collaboration with Zydus Lifesciences for $91.0 million and a sharp reduction in expected annual operating burn to about $50 million from prior levels above $200 million. The proxy seeks approval to add 5,000,000 shares to the 2019 Equity Incentive Plan, expand the Employee Stock Purchase Plan, authorize a one‑time option exchange, approve 2025 executive pay on an advisory basis, elect two directors, and ratify KPMG as auditor.
AGENUS INC director Susan B. Hirsch received a grant of stock options to acquire 105,000 shares of Common Stock. The options have an exercise price of $3.90 per share and were awarded at no cost as a compensation grant.
The award was granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on the one-year anniversary of the grant date. Following this grant, Hirsch holds stock options covering 105,000 underlying shares directly, with an expiration date in 2036.
AGENUS INC director and officer Jennifer Buell received new stock option awards as part of her equity compensation. On April 24, she was granted options to acquire 5,000 shares of common stock and a separate grant covering 300,000 shares, both with an exercise price of $3.90 per share and expiring on April 24, 2036.
The options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vest over three years. One-third of each award vests on April 24, 2027, with the remaining two-thirds vesting in equal quarterly installments thereafter. These are compensation-related grants rather than open-market purchases or sales.
AGENUS INC Chief Medical Officer Steven J. O'Day received two stock option awards covering a total of 165,333 shares of common stock. Both option grants have an exercise price of $3.90 per share and expire on April 24, 2036.
One option for 95,333 shares was awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments thereafter. A second option for 70,000 shares was granted under the same plan in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026.